Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE41.5050
- TODAY'S CHANGE (%)0.8550 (2.1033%)
- Bid / Lots41.4700/ 4
- Ask / Lots41.5600/ 2
- Open / Previous Close41.1600 / 40.6500
- Day Range
- 52 Week Range
- Volume18,641
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 3503 | 41.16 |
| 09:34 ET | 700 | 41.53 |
| 09:38 ET | 260 | 41.48 |
| 09:39 ET | 100 | 41.505 |
| 09:43 ET | 100 | 41.92 |
| 09:45 ET | 100 | 42.135 |
| 09:56 ET | 168 | 41.92 |
| 10:01 ET | 200 | 42.12 |
| 10:15 ET | 100 | 41.97 |
| 10:19 ET | 100 | 41.825 |
| 10:24 ET | 500 | 42.05 |
| 10:26 ET | 905 | 42.075 |
| 10:32 ET | 465 | 42.0021 |
| 10:39 ET | 100 | 42.035 |
| 10:42 ET | 200 | 42.07 |
| 10:44 ET | 746 | 42.235 |
| 10:48 ET | 100 | 42.28 |
| 10:50 ET | 600 | 42.27 |
| 10:51 ET | 500 | 42.065 |
| 10:55 ET | 300 | 42.05 |
| 10:57 ET | 300 | 41.94 |
| 11:02 ET | 197 | 41.785 |
| 11:04 ET | 100 | 41.78 |
| 11:09 ET | 100 | 41.73 |
| 11:11 ET | 500 | 41.7 |
| 11:13 ET | 200 | 41.545 |
| 11:15 ET | 200 | 41.45 |
| 11:20 ET | 400 | 41.515 |
| 11:22 ET | 200 | 41.505 |
Apr 16, 2024
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting, from 8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 12, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham, from 7:13AM ET on Friday Apr 12, 2024 by Dow Jones
7:13AM ET on Friday Apr 12, 2024 by Dow Jones
Apr 10, 2024
DJ Xenon Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 9:57AM ET on Wednesday Apr 10, 2024 by Dow Jones
9:57AM ET on Wednesday Apr 10, 2024 by Dow JonesXenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:30AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 4, 2024
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference, from 4:01PM ET on Thursday Apr 04, 2024 by Dow Jones
4:01PM ET on Thursday Apr 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 3.1B | -15.2x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
IDEAYA Biosciences Inc | 3.0B | -20.8x | --- |
Janux Therapeutics Inc | 2.9B | -42.1x | --- |
Apogee Therapeutics Inc | 2.8B | -28.7x | --- |
Iovance Biotherapeutics Inc | 3.3B | -6.3x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-2.73 |
Book Value | $12.31 |
P/E Ratio | -15.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
